Pressure Reducing Support Surfaces

Number: 0430

Table Of Contents

Policy Applicable CPT / HCPCS / ICD-10 Codes Background References

Bạn đang xem: Pressure Reducing Support Surfaces

Policy

Scope of Policy

This Clinical Policy Bulletin addresses pressure reducing support surfaces.

1. Medical Necessity

   Aetna considers pressure-relieving support surfaces medically necessary as durable medical equipment (DME) according to the selection criteria set forth below.

   1. Group 1 Support Surfaces

      A group 1 mattress overlay or mattress is considered medically necessary DME when the member meets:

      1. Criterion a (below); or
      2. Criteria b or c and at least one of criteria d to g (below):
         1. Completely immobile – i.e., member can not make changes in body position without assistance.
         2. Limited mobility – i.e., member can not independently make changes in body position significant enough to alleviate pressure
         3. Any stage pressure ulcer on trunk or pelvis
         4. Impaired nutritional status
         5. Fecal or urinary incontinence
         6. Altered sensory perception
         7. Compromised circulatory status.

      A group 1 support surface is considered experimental, investigational, or unproven when these criteria are not met because of insufficient evidence in the peer-reviewed literature.

   2. Group 2 Pressure Reducing Support Surfaces

      Alternating Pressure, Low Air Loss Mattresses, Overlays and Underlays

      A group 2 support surface is considered medically necessary DME when the member meets:

      1. Criteria a and b and c (below); or
      2. Criterion d; or
      3. Criteria e and f (below):
         1. The member has multiple stage II (partial thickness skin loss) pressure ulcers located on the trunk or pelvis.
         2. The member has been on a comprehensive ulcer treatment programFootnote* for at least the past month, which has included the use of an appropriate group 1 support surface.
         3. The member’s ulcers have worsened or remained the same over the past month.
         4. The member has large or multiple stage III (full thickness tissue loss) or stage IV (deep tissue destruction) pressure ulcer(s) on the trunk or pelvis.
         5. The member has had a recent myocutaneous flap or skin graft for a pressure ulcer on the trunk or pelvis (surgery within the past 60 days).
         6. The member has been on a group 2 or 3 support surface immediately prior to a recent discharge from a hospital or nursing facility (discharge within the past 30 days).

      If the member is on a group 2 surface, there should be a care plan established by the physician or home care nurse, which includes the above elements.

      When a group 2 support surface is prescribed for a myocutaneous flap or skin graft, continued use is generally considered medically necessary for up to 60 days from the date of surgery.

      Use of a group 2 support surface is considered medically necessary until the ulcer is healed or, if healing does not continue, there is documentation in the medical record to show:

      1. Other aspects of the care plan are being modified to promote healing, or
      2. The use of the alternating pressure mattress is medically necessary for wound management.

      A group 2 support surface is considered experimental, investigational, or unproven when these criteria are not met because of insufficient evidence in the peer-reviewed literature.

   3. Group 3 Pressure Reducing Support Surfaces

      Air-Fluidized Beds (Bead Beds)

      An air-fluidized bed is considered medically necessary DME only if all of the following criteria are met:

      1. 1. The member has a stage III (full thickness tissue loss) or stage IV (deep tissue destruction) pressure ulcer

            1. A stage III or stage IV pressure ulcer of the foot does not require an air-fluidized bed because the foot can be elevated to relieve pressure;
            2. If the member is on an air-fluidized bed and an ulcer is less than 8 square centimeters and/or it is in an area other than the posterior trunk or pelvis, the attending physician must document why an alternative support surface would not be medically effective;
         2. The member is bedridden or chair bound as a result of severely limited mobility;
         3. In the absence of an air-fluidized bed, the member would require institutionalization (i.e., hospitalization or placement in a nursing home);
         4. The air-fluidized bed is ordered in writing by the member’s attending physician based upon a comprehensive assessment and evaluation of the member after conservative treatmentFootnote** has been tried without success. The evaluation generally must be performed within a week prior to initiation of therapy with the air-fluidized bed;
         5. A trained adult caregiver is available to assist the member with activities of daily living, fluid balance, dry skin care, repositioning, recognition and management of altered mental status, dietary needs, prescribed treatments, and management and support of the air-fluidized bed system and its problems such as leakage;
         6. A physician directs the home treatment regimen, and reevaluates and recertifies the need for the air-fluidized bed on a monthly basis;
         7. All other alternative equipments have been considered and ruled out.

      The member must generally have been on the conservative treatment program for at least 1 month prior to use of the air-fluidized bed with worsening or no improvement of the ulcer.

      Continued use of an air-fluidized bed is considered medically necessary until the ulcer is healed, or if healing does not continue, there is documentation in the medical record to show that:

      1. Other aspects of the care plan are being modified to promote healing; or
      2. The use of the bed is medically necessary for wound management.

      Examples of brands of group 3 support surfaces (air-fluidized beds) include the Clinitron, the Envella Bed, Fluid Air, and Mediscus Heavy Duty System.

   4. Sheepskin and Lambswool Pads

      Medical necessity criteria for sheepskin and lambswool pads are the same as for alternating pressure pads and mattresses (group 2 pressure-reducing support surfaces).

   5. Decubitus Care Accessories

      1. Bed blanket cradle (keeps bed covers from touching affected skin) are considered medically necessary for diabetic ulcers, decubiti or burns, or gouty arthritis.
      2. Heel or elbow protectors are considered medically necessary.

   6. Bottoming Out

      For all types of support surfaces, the support surface provided for the member should be one in which the member does not “bottom out”. Bottoming out is the finding that an outstretched hand can readily palpate the bony prominence (coccyx or lateral trochanter) when it is placed palm up between the undersurface of the overlay or mattress and in an area under the bony prominence. This bottoming out criterion should be tested with the member in the supine position with their head flat, in the supine position with their head slightly elevated (no more than 30 degrees), and in the sidelying position. Support surfaces that do not prevent bottoming out are considered not medically necessary.

2. Experimental, Investigational, or Unproven

   1. An air-fluidized bed is considered experimental, investigational, or unproven when the afore-mentioned criteria are not met because of insufficient evidence in the peer-reviewed literature.
   2. An air-fluidized bed has no proven value for persons with any of the following contraindications:
      1. Electrical system is insufficient for the anticipated increase in energy consumption;
      2. Structural support is inadequate to support the weight of the air-fluidized bed system (it generally weighs 1,600 pounds or more);
      3. The caregiver is unwilling or unable to provide the type of care required by the patient on an air-fluidized bed;
      4. The member has co-existing pulmonary disease (the lack of firm back support makes coughing ineffective and dry air inhalation thickens pulmonary secretions);
      5. The member requires treatment with wet soaks or moist wound dressings that are not protected with an impervious covering such as plastic wrap or other occlusive material; or
      6. Other known contraindications to use of an air-fluidized bed exist.

3. Policy Limitations and Exclusions

   1. Air-fluidized bed

      Coverage of an air-fluidized bed is limited to the equipment itself. Architectural adjustments such as electrical or structural improvements for the air-fluidized bed are generally excluded from coverage. In addition, services of informal caregivers are excluded from coverage. Please check benefit plan descriptions.

   2. Ordinary air mattresses

      Aetna does not cover air mattresses other than alternating air mattresses and low-air-loss beds because they do not meet Aetna’s contractual definition of durable medical equipment (i.e., because they are not durable (made to withstand prolonged use), not mainly used in the treatment of disease or injury, and are normally of use to persons who do not have a disease or injury. Please check benefit plan descriptions for details. The following are examples of brand names of air mattresses that are not covered:

      1. Air Flow Mat air-filled vibrating mattress
      2. Air-O-Pad air mattress.

Table:

CPT Codes / HCPCS Codes / ICD-10 Codes

Code Code Description

Information in the [brackets] below has been added for clarification purposes. &nbspCodes requiring a 7th character are represented by “+”:

Pressure reducing support surfaces:

HCPCS codes covered if selection criteria are met:

A4640 Replacement pad for use with medically necessary alternating pressure pad owned by patient E0181 Powered pressure reducing mattress overlay/pad, alternating, with pump, includes heavy duty E0182 Pump for alternating pressure pad, for replacement only E0183 Powered pressure reducing underlay/pad, alternating, with pump, includes heavy duty E0184 Dry pressure mattress E0185 Gel or gel-like pressure pad for mattress, standard mattress length and width E0186 Air pressure mattress E0187 Water pressure mattress E0188 Synthetic sheepskin pad E0189 Lambswool sheepskin pad, any size E0191 Heel or elbow protector, each E0193 Powered air flotation bed (low air loss therapy) E0196 Gel pressure mattress (nonpowered) E0197 Air pressure pad for mattress, standard mattress length and width E0198 Water pressure pad for mattress, standard mattress length and width E0199 Dry pressure pad for mattress, standard mattress length and width E0277 Powered pressure-reducing air mattress E0280 Bed cradle, any type E0370 Air pressure elevator for heel E0371 Nonpowered advanced pressure reducing overlay for mattress, standard mattress length and width E0372 Powered air overlay for mattress, standard mattress length and width E0373 Nonpowered advanced pressure reducing mattress

ICD-10 codes covered if selection criteria are met (not all-inclusive):

L89.101 – L89.159 Pressure ulcer of back L89.200 – L89.229 Pressure ulcer of hip L89.301 – L89.329 Pressure ulcer of buttock L89.40 – L89.45 Pressure ulcer of contiguous site of back, buttock and hip L89.810 – L89.899 Pressure ulcer of other site R40.0 Somnolence R40.1 Stupor R40.3 Persistent vegetative state R40.4 Transient alteration of awareness Z74.01 Bed confinement status

Air-fluidized beds:

HCPCS codes covered if selection criteria are met:

E0194 Air fluidized bed

ICD-10 codes covered if selection criteria are met (not all-inclusive):

I96 Gangrene, not elsewhere classified L89.101 – L89.159 Pressure ulcer of back L89.200 – L89.229 Pressure ulcer of hip L89.301 – L89.329 Pressure ulcer of buttock L89.40 – L89.45 Pressure ulcer of contiguous site of back, buttock and hip R64 Cachexia Z74.01 Bed confinement status

ICD-10 codes not covered for indications listed in the CPB:

J40 – J47.9 Chronic lower respiratory diseases J86.0 – J94.9J96.00 – J99 Other diseases of respiratory system L89.500 – L89.629 Pressure ulcer of ankle or heel M86.071 – M86.079M86.171 – M86.179M86.271 – M86.279M86.371 – M86.379M86.471 – M86.479M86.571 – M86.579M86.671 – M86.679M86.8×7, M86.9M89.671 – M89.679M90.871 – M90.879 Osteomyelitis, periostitis, and other infections involving bone, ankle and foot

Background

Pressure relieving support surfaces are designed to prevent or promote the healing of pressure ulcers by reducing or eliminating tissue interface pressure. Most of these devices reduce interface pressure by conforming to the contours of the body so that pressure is distributed over a larger surface area rather than concentrated on a more circumscribed location.

The purpose of this clinical policy bulletin (CPB) is to provide guidance on selection of support surfaces. This assessment provides a comparative evaluation of alternating air mattresses (such as the Pegasus Airwave System), air-fluidized beds (such as the Clinitron bed), and low-air-loss mattresses (such as the Flexicair bed). This CPB addresses coverage of mattress overlays and underlays, specialized mattresses and specialty beds. Such devices are made entirely of foam, are constructed of an outer membrane that encases a gel, foam, air, water, or polyfill, or are engineered to fluidize ceramic beads.

This clinical policy on pressure-relieving support surfaces is based on Medicare criteria and on the recommendations of the AHCPR Treatment of Pressure Ulcers Guidelines Panel. Use of low-air-loss beds and air-fluidized beds is reserved for patients with stage III and stage IV ulcers. Because pressure-reducing support surfaces can be developed and marketed without efficacy studies, few data exist to recommend their rational use. In the absence of evidence demonstrating differences in efficacy between air-fluidized beds, low-air-loss beds, and alternating air mattresses, it is reasonable to reserve treatment with the most expensive of these 3 types of support surfaces to patients with ulcers that have failed to heal with one of the other types of beds.

The AHCPR Guidelines on Treatment of Pressure Ulcers (1994) provides an algorithm for selection of overlays and mattresses. Low-air-loss beds and air-fluidized beds are reserved for patients with multiple, large, truncal stage III or IV ulcers and for patients who have bottomed out on a dynamic overlay or mattress. It is reasonable to first try a low-air-loss bed (such as a Flexair) or a dynamic overlay (such as a Pegasus Airwave) and progress to an air-fluidized bed (such as a Clinitron) if it appears that the patient’s ulcer is not healing properly.

No conclusions about the comparative efficacy of the low-air-loss bed, the alternating air mattress, and the air-fluidized bed can be drawn from available evidence because of a lack of studies that compare these support surfaces to each other. Published studies of support surfaces have compared air-flotation beds or alternating air mattresses to static support surfaces or regular mattresses. The Treatment of Pressure Ulcers Guidelines Panel found that “[n]o studies have compared the effectiveness of low-air-loss beds and air-fluidized beds.” The Panel concluded that “[a] randomized controlled trial will be required to compare low-air-loss bed and air-fluidized bed therapy.”

An issue of Clinics in Geriatric Medicine (Remsberg and Bennett, 1997) was devoted to treatment of pressure ulcers. Experts on pressure ulcers, including several members of the AHCPR’s Treatment of Pressure Ulcers Guidelines Panel, reviewed the medical literature that has appeared since the publication of the AHCPR pressure ulcer guidelines. Remsberg and Bennett (1997) reviewed the literature on overlays, replacement mattresses, and specialty beds. The authors concluded: “Expensive low-air-loss beds and air-fluidized beds have been inadequately studied, and their use is usually driven by reimbursement issues and the experience and biases of nurses and physicians. Although 2 randomized prospective trials showed that healing rates were statistically superior for these expensive devices, one study did not demonstrate superior healing. In all of these studies, some patients developed new sores despite treatment on the specialty surfaces. In addition to statistical superiority, clinical significance must also be evaluated. For example, in the only randomized trial assessing the efficacy of air-fluidized beds, even the authors noted that the reported outcome differences (0.5 cm2 median increase in surface area in the control group versus 1.2 cm2 median decrease in the treatment group) were hardly clinically impressive. In a large retrospective descriptive study, the observation was made that many patients who were admitted to a long-stay hospital for treatment of severe pressure sores on air-fluidized beds died within the first 30 days after admission. Since no discernible pressure sore healing occurred for these patients before they died, the issue of futility must be considered when making treatment decisions for similar patients”.

In a Cochrane review, McInnes et al (2011) evaluated the effects of pressure-relieving support surfaces in the treatment of pressure ulcers. These investigators searched the Cochrane Wounds Group Specialised Register (searched July 15, 2011); The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 3); Ovid MEDLINE (2007 to Week 1 of July 2011); Ovid MEDLINE (In-Process & Other Non-Indexed Citations, July 14, 2011); Ovid EMBASE (2007 to Week 27 of 2011); EBSCO CINAHL (2007 to July 14, 2011). The reference sections of included studies were also searched. They included published or unpublished randomized controlled trials (RCTs) that assessed the effects of support surfaces for treating pressure ulcers, in any patient group or setting that reported an objective measure of wound healing. Data extraction and assessment of risk of bias were performed independently by 2 review authors. Trials with similar patients, comparisons and outcomes were considered for pooled analysis. Where pooling was inappropriate the results of the trials were reported narratively. Where possible, the risk ratio or mean difference was calculated for the results of individual studies. These researchers identified 18 trials of support surfaces for pressure ulcer treatment, involving 1,309 participants with samples sizes that ranged from 14 to 160. Of 3 trials comparing air-fluidized devices with conventional therapy, 2 reported significant reductions in pressure ulcer size associated with air-fluidized devices. Due to lack of reported variance data these investigators could not replicate the analyses. In relation to 3 of the trials that reported significant reductions in pressure ulcer size favoring low air loss devices compared with foam alternatives, they found no significant differences. A small trial found that sheepskin placed under the legs significantly reduced redness and similarly a small subgroup analysis favored a profiling bed compared with a standard bed in terms of the healing of existing grade 1 pressure ulcers. Poor reporting, clinical heterogeneity, lack of variance data and methodological limitations in the eligible trials meant that no pooled comparisons were undertaken. The authors concluded that there is no conclusive evidence about the superiority of any support surface for the treatment of existing pressure ulcers. Methodological issues included variations in outcomes measured, sample sizes and comparison groups. Many studies had small sample sizes and often there was inadequate description of the intervention, standard care and co-interventions. Individual study results were often inadequately reported, with failure to report variance data common, thus hindering the calculation of mean differences. Some studies did not report P values when reporting on differences in outcomes. In addition, the age of some trials (some being 20 years old), meant that other technologies may have superseded those investigated. They stated that further and rigorous studies are required to address these concerns and to improve the evidence base before firm conclusions can be drawn about the most effective support surfaces to treat pressure ulcers.

Colin et al (2012) stated that the use of support surfaces in the prevention and treatment of pressure ulcers prevention is an important part of care for a patient at risk and/or suffering from sore(s). These researchers examined which support surfaces to use in prevention and treatment of at-risk and/or pressure sore patients. They performed a systematic review of the literature querying the several Pascal Biomed, PubMed and Cochrane Library databases from 2000 through 2010. In prevention, a structured foam mattress is more efficient than a standard hospital mattress. An alternating pressure mattress is more effective than a visco-elastic mattress limiting the occurrence heel pressure ulcers, but those that do occur are more serious. A low-air-loss bed is more efficient than a mixed pulsating air mattress in prevention of heel pressure ulcers. Some types of sheepskin can reduce sacral pressure ulcer incidence in orthopedic patients. Use of an overlay on an operating table limits the occurrence of peri-operative and post-operative pressure ulcers. An air-fluidized bed improves pressure ulcer healing. The authors concluded that the data in the literature are not always relevant and do not suffice to dictate a clinician’s choices. These investigators noted that they were compelled to recognize the methodological limitations of many studies, the lack of corporate interest in conducting such studies and the relatively small number of available trials. However, the effectiveness of some support surfaces reaches a sufficient level of evidence, especially when they are associated with postural, hydration and nutritional measures. They stated that support surfaces are recommended in prevention and treatment of patients at risk and/or already suffering from pressure ulcer, and their use should constitute part of an overall preventive or curative strategy.

Tricco et al (2015) stated that numerous, often multi-faceted regimens are available for treating complex wounds, yet the evidence of these interventions is recondite across the literature. These researchers identified effective interventions to treat complex wounds through an overview of systematic reviews. MEDLINE (OVID interface, 1946 until October 26, 2012), EMBASE (OVID interface, 1947 until October 26, 2012), and the Cochrane Database of Systematic Reviews (Issue 10 of 12, 2012) were searched on October 26, 2012. Systematic reviews that examined adults receiving care for their complex wounds were included. Two reviewers independently screened the literature, abstracted data, and assessed study quality using the Assessment of Multiple Systematic Reviews (AMSTAR) tool. Overall, 99 systematic reviews were included after screening 6,200 titles and abstracts and 422 full-texts; 54 were systematic reviews with a meta-analysis (including data on over 54,000 patients) and 45 were systematic reviews without a meta-analysis. Overall, 44 % of included reviews were rated as being of high quality (AMSTAR score greater than or equal to 8). Based on data from systematic reviews including a meta-analysis with an AMSTAR score greater than or equal to 8, promising interventions for complex wounds were identified. These included bandages or stockings (multi-layer, high compression) and wound cleansing for venous leg ulcers; 4-layer bandages for mixed arterial/venous leg ulcers; biologics, ultrasound, and hydrogel dressings for diabetic leg/foot ulcers; hydrocolloid dressings, electrotherapy, air-fluidized beds, and alternate foam mattresses for pressure ulcers; and silver dressings and ultrasound for unspecified mixed complex wounds. For surgical wound infections, topical negative pressure and vacuum-assisted closure were promising interventions, but this was based on evidence from moderate to low quality systematic reviews. The authors concluded that numerous interventions can be utilized for patients with varying types of complex wounds, yet few treatments were consistently effective across all outcomes throughout the literature. Clinicians and patients can use these results to tailor effective treatment according to type of complex wound. Network meta-analysis will be of benefit to decision-makers, as it will permit multiple treatment comparisons and ranking of the effectiveness of all interventions.

Griffey and colleagues (2021) stated that healing of severe pressure injuries (PIs) in patients with multiple co-morbidities requires a multi-faceted and inter-disciplinary approach and includes the use of support surfaces. Published clinical data guiding support surface selection are very limited. Long-term acute care hospitals frequently treat medically complex patients, many with severe PIs. In a case-series study, these researchers compared healing rates in patients with severe PIs on air-fluidized therapy (AFT) or fluid immersion system (FIS) support surfaces. After obtaining informed consent, patients with a stage 3 or 4 PI were randomized to receive either AFT or FIS in addition to the standard of care (SOC). Baseline and weekly wound measurements were obtained using a 3-dimensional (3D) camera measurement tool. The required sample size was calculated to be 60. After the study had started, the long-term acute care hospital admission criteria changed, severely limiting the number of patients who met the study inclusion criteria. Only 4 patients with a stage 4 PI completed the study. Of those, 2 were on an AFT and 2 were on an FIS surface. All wounds reduced in size; 0.12 and 0.57 cm²/day for patients on AFT and 0.68 and 1.34 cm²/day for patients on FIS. All but 1 wound had a reduction in wound volume ranging from -0.2 and 0.97 cm³ to 1.78 and 4.18 cm³/day for patients on AFT and FIS, respectively. The authors concluded that obtaining much-needed evidence to guide support surface selections for patients with severe PIs is challenging and requires multi-center studies. These researchers noted that this trial did not achieve enrollment goals; they presented the data that were available and recognized the limited generalizability of these data. These investigators stated that more research using larger sample sizes, is needed to determine the therapeutic benefit of these measures to enable evidence-based decision-making.

According to the Wound Systems website, the Dolphin Bed surface replaces the standard hospital bed mattress and is also available in bariatric sizes. The pump/controller fits on the foot of the bed and includes an onboard rechargeable battery for power interruption protection and mobility. Battery operation capability also permits the controller to be adapted to a wheelchair, providing a continuum of pressure reduction wound care and patient mobility. The application of the Fluid Immersion Simulation technology provides dynamic pressure reduction adjustments every 11 seconds to keep the patient at equilibrium. The Dolphin System is often used as a clinically effective, cost reduced alternative to Air Fluidized Therapy (AFT).

Fluidized Positioner for the Prevention of Occipital Pressure Injury

In a quality improvement project, Byfield (2022) examined if head immobilization, pressure re-distribution for the occiput, and off-loading of pressure from craniotomy incisions could be improved by means of fluidized positioners instead of pillows previously used as the SOC. A total of 8 patients with head trauma and craniotomy in a surgical intensive care unit (SICU) and cardiovascular intensive care unit (CVICU) from a level 1 trauma center in the Southeast region of the U.S. participated over a 6-month period. The project comprised educating staff including nurses, nursing assistants, supervisors, and care managers, and implementation of the head positioner from July 2018 to December 2018. Staff from the SICU and CVICU, a step-down unit, and a neurological ICU were also educated on the use of a fluidized positioner, because patients were transferred to these units when stable. All patients who underwent craniotomy surgery were placed on the fluidized positioner post-operatively until immobilization and off-loading were no longer required. During the initial 6-month evaluation period, no new pressure injuries (PIs) or incisional trauma occurred in the 8 patients. The economic impact to treat 1 hospital-acquired unstageable PI was estimated at $78,722. Because no new occipital PIs occurred in the 8 patients placed on the fluidized head positioner, the hospital potentially saved $629,776. The authors concluded that the findings from the project suggested that implementation of a fluidized positioner could re-distribute pressure to the occiput, off-load craniotomy incision sites, and prevent PIs. These preliminary findings need to be validated by well-designed studies.

Fluidized Positioner for the Prevention of Skin and Mucosal Damage in Patients with COVID-19

Singh and colleagues (2020) noted that patients admitted to the ICU are at a high risk for developing PIs. A patient requiring multi-organ support is at a higher risk for PIs related to immobility, sedation, vasopressors, and hypoxia. To mitigate PIs, the authors’ hospital employs a bundle approach to prevent skin injury. However, despite efforts to prevent PIs, these investigators found that their patients in the ICU with the diagnosis of COVID-19 went on to develop significant pressure and mucosal injuries. This was a case-series study of 4 patients diagnosed with COVID-19 who developed significant skin and mucosal injuries during their ICU admissions in March 2020. These researchers found that patients developed skin conditions that were initially thought to be deep-tissue injuries (DTIs) early in the admission. The DTIs progressed over the course of the admission in the ICU and evolved to thick adherent eschar that appeared to be unstageable PIs, which extended beyond the soft tissue directly over the bony prominence. These investigators also found that skin damage to the mucosa of the nares, tongue, lips, and urethra presented first as inflammation and then progressed to thick eschar. Despite maximum pressure relief with the use of a pressure-relieving turn and position system, bordered foam dressings, fluidized positioners, specialty beds, and leadership support for twice-weekly skin checks, these COVID-19 patients developed extensive skin damage across the fleshy portion of the buttocks and on the mucosa of the nares, tongue, lips, and urethra during minimal exposure to pressure. The authors concluded that although the initial presentation of the skin damage appeared to be related to pressure, the extent of the skin damage suggested a vascular inflammatory process beyond skin damage related to pressure.

Appendix

Xem thêm : Probióticos

Patients using pressure-reducing support surfaces should have a care plan, which has been established by the patient’s physician and home care nurse, which is documented in the patient’s medical records, and which generally should include the following:

The following are definitions and instructions relevant to interpretation of this policy.

Pressure Ulcer Staging

The staging of pressure ulcers used in this policy is as follows:

Table: Staging of Pressure Ulcers Stages Descriptions Stage I Non-blanchable erythema of intact skin Stage II Partial thickness skin loss involving epidermis and/or dermis Stage III Full thickness skin loss involving damage or necrosis of subcutaneous tissue that may extend down to, but not through, underlying fascia Stage IV Full thickness skin loss with extensive destruction, tissue necrosis or damage to muscle, bone, or supporting structures

Group 1 Support Surfaces

The following are considered group 1 support surfaces: pressure pads for mattresses, non-powered pressure reducing mattresses, and powered pressure reducing mattress overlay systems. Each of the support surfaces described below is considered medically necessary when criteria for group 1 support surfaces are met.

Pressure pads for mattresses are non-powered pressure-reducing mattress overlays. These devices are designed to be placed on top of a standard hospital or home mattress. Pressure pads for mattresses with the following features are considered medically necessary when criteria for group 1 support surfaces are met:

• Only foam mattress overlays with all of the following features are considered group 1 support surfaces:

  Non-powered pressure reducing mattresses with the following features are considered medically necessary when criteria for a group 1 support surface are met:

• Only foam mattresses with all of the following features are considered group 1 support surfaces:

  • Foam with a density and other qualities that provide adequate pressure reduction.

• Only air, water, or gel mattresses with all of the following features are considered group 1 support surfaces:

Powered pressure reducing mattress overlay systems (alternating pressure or low air loss) are considered group 1 support surfaces only if all of the following features are present:

Examples of group 1 support surfaces include the WAFFLE Brand Air Insert With Foam Base, the WAFFLE Brand Static Air Mattress Overlay, and the Aquatherm Tender-Clous Static Air System.

Group 2 Support Surfaces

The following are considered group 2 support surfaces: powered pressure reducing mattresses, semi-electric or total electric hospital beds with powered pressure reducing mattresses, powered pressure reducing mattress overlays and underlays, advanced non-powered pressure reducing mattresses, and advanced non-powered pressure reducing mattress overlays and underlays. Each of the support surfaces described below is considered medically necessary when criteria for group 2 support surfaces are met.

A powered pressure reducing mattress (alternating pressure low air loss, or powered flotation without air loss) is considered a group 2 support surface only if all of the following features are present:

Semi-electric or total electric hospital beds with fully integrated powered pressure-reducing mattresses that have all of the features described above are considered group 2 support surfaces.

An advanced non-powered pressure-reducing mattress overlay is considered a group 2 support surface if all of the following features are present:

A powered pressure reducing mattress overlay/underlay (low air loss, powered flotation without low air loss, or alternating pressure) is considered a group 2 support surface if all of the following features are present:

An advanced non-powered pressure-reducing mattress is considered a group 2 support surface if all of the following features are present:

Examples of group 2 pressure reducing support surfaces include the ROHO Dry Flotation Mattress System, the Flexicare Low-Air-Loss Bed, the Mediscus Air Support Therapy, the Grand Dyna-Care Alternating Pressure-Relief Seat Pad, and the Aquatherm Deluxe Alternating Pressure Pad.

Group 3 Support Surfaces

Group 3 support surfaces include air-fluidized beds. An air-fluidized bed uses warm air under pressure to set small ceramic beads in motion which simulate the movement of fluid. When the member is placed in the bed, his body weight is evenly distributed over a large surface area, which creates the sensation of “floating.” Air-fluidized beds are considered medically necessary when the criteria for group 3 support surfaces are met.

Note that pressure-reducing support surfaces containing multiple components are categorized according to the clinically predominant component (usually the topmost layer of a multi-layer product).

A support surface that does not meet the characteristics specified in the support surface policy will usually be considered not medically necessary.

References

Nguồn: https://buycookiesonline.eu
Danh mục: Info